U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Cutaneous Melanoma

MedGen UID:
1728947
•Concept ID:
C5419184
•
Neoplastic Process

Definition

Cutaneous melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Cutaneous Melanoma

Professional guidelines

PubMed

Revolutionizing treatment of advanced melanoma with immunotherapy.
Carreau N, Pavlick A
Surg Oncol 2022 Jun;42:101180. Epub 2019 Jan 12 doi: 10.1016/j.suronc.2019.01.002. PMID: 30691991
Clinical treatment options for early-stage and advanced conjunctival melanoma.
Zeng Y, Hu C, Shu L, Pan Y, Zhao L, Pu X, Wu F
Surv Ophthalmol 2021 May-Jun;66(3):461-470. Epub 2020 Sep 25 doi: 10.1016/j.survophthal.2020.09.004. PMID: 32980421
Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR, Mehnert JM
Cancer Treat Res 2016;167:295-320. doi: 10.1007/978-3-319-22539-5_13. PMID: 26601869

Recent clinical studies

Etiology

Acral melanoma: clinical advances and hope for the future.
Perez MC, Messina JL, Karapetyan L, Neves RI, Sondak VK
Clin Adv Hematol Oncol 2023 Aug;21(8):400-409. PMID: 37530614
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.
Leeneman B, Blommestein HM, Coupé VMH, Hendriks MP, Kruit WHJ, Plaisier PW, van Ruth S, Ten Tije AJ, Wouters MWJM, Franken MG, Uyl-de Groot CA
Melanoma Res 2021 Jun 1;31(3):249-257. doi: 10.1097/CMR.0000000000000732. PMID: 33871398
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G
Ann Oncol 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. PMID: 31566658
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S
Lancet 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. PMID: 30238891
Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR, Mehnert JM
Cancer Treat Res 2016;167:295-320. doi: 10.1007/978-3-319-22539-5_13. PMID: 26601869

Diagnosis

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV
Cancer Cell 2022 Jan 10;40(1):88-102.e7. Epub 2021 Dec 23 doi: 10.1016/j.ccell.2021.11.012. PMID: 34951955
Revolutionizing treatment of advanced melanoma with immunotherapy.
Carreau N, Pavlick A
Surg Oncol 2022 Jun;42:101180. Epub 2019 Jan 12 doi: 10.1016/j.suronc.2019.01.002. PMID: 30691991
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.
Leeneman B, Blommestein HM, Coupé VMH, Hendriks MP, Kruit WHJ, Plaisier PW, van Ruth S, Ten Tije AJ, Wouters MWJM, Franken MG, Uyl-de Groot CA
Melanoma Res 2021 Jun 1;31(3):249-257. doi: 10.1097/CMR.0000000000000732. PMID: 33871398
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G
Ann Oncol 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. PMID: 31566658
Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR, Mehnert JM
Cancer Treat Res 2016;167:295-320. doi: 10.1007/978-3-319-22539-5_13. PMID: 26601869

Therapy

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N
Nat Med 2022 Mar;28(3):535-544. Epub 2022 Feb 28 doi: 10.1038/s41591-022-01695-5. PMID: 35228751Free PMC Article
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV
Cancer Cell 2022 Jan 10;40(1):88-102.e7. Epub 2021 Dec 23 doi: 10.1016/j.ccell.2021.11.012. PMID: 34951955
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma.
Marconcini R, Pezzicoli G, Stucci LS, Sergi MC, Lospalluti L, Porta C, Tucci M
Hum Vaccin Immunother 2022 May 31;18(3):1980315. Epub 2021 Oct 6 doi: 10.1080/21645515.2021.1980315. PMID: 34613889Free PMC Article
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G
Ann Oncol 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. PMID: 31566658
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S
Lancet 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. PMID: 30238891

Prognosis

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N
Nat Med 2022 Mar;28(3):535-544. Epub 2022 Feb 28 doi: 10.1038/s41591-022-01695-5. PMID: 35228751Free PMC Article
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV
Cancer Cell 2022 Jan 10;40(1):88-102.e7. Epub 2021 Dec 23 doi: 10.1016/j.ccell.2021.11.012. PMID: 34951955
Clinical treatment options for early-stage and advanced conjunctival melanoma.
Zeng Y, Hu C, Shu L, Pan Y, Zhao L, Pu X, Wu F
Surv Ophthalmol 2021 May-Jun;66(3):461-470. Epub 2020 Sep 25 doi: 10.1016/j.survophthal.2020.09.004. PMID: 32980421
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S
Lancet 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. PMID: 30238891
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T, Kim KB
Clin Exp Metastasis 2018 Aug;35(5-6):503-520. Epub 2018 Jul 17 doi: 10.1007/s10585-018-9913-y. PMID: 30019239

Clinical prediction guides

A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG
Int J Cancer 2024 May 15;154(10):1760-1771. Epub 2024 Jan 31 doi: 10.1002/ijc.34853. PMID: 38296842
Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.
Schäfer H, Subbarayan K, Massa C, Vaxevanis C, Mueller A, Seliger B
J Transl Med 2023 Sep 20;21(1):643. doi: 10.1186/s12967-023-04476-x. PMID: 37730606Free PMC Article
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N
Nat Med 2022 Mar;28(3):535-544. Epub 2022 Feb 28 doi: 10.1038/s41591-022-01695-5. PMID: 35228751Free PMC Article
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV
Cancer Cell 2022 Jan 10;40(1):88-102.e7. Epub 2021 Dec 23 doi: 10.1016/j.ccell.2021.11.012. PMID: 34951955
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T, Kim KB
Clin Exp Metastasis 2018 Aug;35(5-6):503-520. Epub 2018 Jul 17 doi: 10.1007/s10585-018-9913-y. PMID: 30019239

Recent systematic reviews

Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics.
Mahdiabadi S, Momtazmanesh S, Karimi A, Rezaei N
Expert Rev Anticancer Ther 2023 Jul-Dec;23(12):1281-1293. Epub 2023 Dec 8 doi: 10.1080/14737140.2023.2278509. PMID: 37908134
Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.
Beaudoux O, Oudart JB, Riffaud L, Visseaux L, Marchal A, Lebre AS, Grange F
Mol Diagn Ther 2022 Mar;26(2):189-202. Epub 2022 Feb 23 doi: 10.1007/s40291-021-00572-0. PMID: 35195858
Rational use of (18)F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review.
Bisschop C, de Heer EC, Brouwers AH, Hospers GAP, Jalving M
Crit Rev Oncol Hematol 2020 Sep;153:103044. Epub 2020 Jul 1 doi: 10.1016/j.critrevonc.2020.103044. PMID: 32673997
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G
Ann Oncol 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. PMID: 31566658
Electrochemotherapy for the Treatment of Unresectable Locoregionally Advanced Cutaneous Melanoma: A Systematic Review.
Aguado-Romeo MJ, Benot-López S, Romero-Tabares A
Actas Dermosifiliogr 2017 Mar;108(2):91-97. Epub 2016 Oct 18 doi: 10.1016/j.ad.2016.08.008. PMID: 27769538

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...